CL2019003161A1 - Métodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents

Métodos de tratamiento selectivo del asma usando antagonistas de il-17.

Info

Publication number
CL2019003161A1
CL2019003161A1 CL2019003161A CL2019003161A CL2019003161A1 CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1 CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1
Authority
CL
Chile
Prior art keywords
antagonists
selective
treatment methods
asthma treatment
asthma
Prior art date
Application number
CL2019003161A
Other languages
English (en)
Spanish (es)
Inventor
Sarah Schmidt Grant
Shamsah Kazani
Edward Khokhlovich
Jason Laramie
Robert Martin Strieter
Tricia Ann Thornton-Wells
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019003161A1 publication Critical patent/CL2019003161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CL2019003161A 2017-05-05 2019-11-04 Métodos de tratamiento selectivo del asma usando antagonistas de il-17. CL2019003161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
CL2019003161A1 true CL2019003161A1 (es) 2020-02-07

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003161A CL2019003161A1 (es) 2017-05-05 2019-11-04 Métodos de tratamiento selectivo del asma usando antagonistas de il-17.

Country Status (13)

Country Link
US (1) US10676522B2 (enExample)
EP (1) EP3619536A1 (enExample)
JP (1) JP2020518604A (enExample)
KR (1) KR20190142398A (enExample)
CN (1) CN110582702A (enExample)
AU (1) AU2018263159A1 (enExample)
BR (1) BR112019023141A2 (enExample)
CA (1) CA3062179A1 (enExample)
CL (1) CL2019003161A1 (enExample)
MX (1) MX2019013160A (enExample)
RU (1) RU2019139387A (enExample)
TW (1) TW201842933A (enExample)
WO (1) WO2018203289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP2023521909A (ja) * 2020-04-17 2023-05-25 イーライ リリー アンド カンパニー 呼吸器疾患の治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック, インコーポレイテッド 好酸球性疾患の診断及び治療方法
WO2015191783A2 (en) * 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
JP2020518604A (ja) 2020-06-25
WO2018203289A1 (en) 2018-11-08
AU2018263159A1 (en) 2019-11-07
EP3619536A1 (en) 2020-03-11
MX2019013160A (es) 2020-02-05
TW201842933A (zh) 2018-12-16
US10676522B2 (en) 2020-06-09
CN110582702A (zh) 2019-12-17
US20180319881A1 (en) 2018-11-08
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07
BR112019023141A2 (pt) 2020-07-28
CA3062179A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CO2019011995A2 (es) Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
CL2015002807A1 (es) Terapia de combinación
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MX2015010724A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
UY34654A (es) Inhibidores de la beta-secretasa
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
AR101476A1 (es) Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
UY34991A (es) Inhibidores de la beta-secretasa